Utebzi is an FDA approved oral antibacterial indicated for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, in adults with limited or no alternative oral treatment options. As the first and only FDA-approved oral carbapenem, it represents a significant advancement in the management of serious bacterial infections while supporting outpatient treatment strategies. For clinical trial and first-to-file teams, monitoring Utebzi’s market adoption, exclusivity timeline, and availability will be important, as it may emerge as a relevant comparator in infectious disease and antibacterial drug development studies.